



RECEIVED
JAN 03 2002
TECH CENTER 1600/2900 #7


Attorney's Docket No.: B0801/7202 AWS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Weiner et al.
Serial No: 09/809,745
Filed: March 15, 2001
For: SUPPRESSION OF VASCULAR DISORDERS BY MUCOSAL
ADMINISTRATION OF HEAT SHOCK PROTEIN PEPTIDES
Examiner: Unknown
Art Unit: 1646

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 30th day of November, 2001.


Yvonne M. Lingo

Commissioner For Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- ☒ [X] Supplemental Information Disclosure Statement
- ☒ [X] PTO Form 1449 with cited references
- ☒ [X] Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No fee is enclosed. If a fee is necessary, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,



Alan W. Steele, Reg. No.: 45,128
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Attorneys for Applicants

Docket No. B0801/7202
Date: November 30, 2001
xnddx

578659.1



ATTORNEY'S DOCKET NO: B0801/7202 (AWS)

RECEIVED

JAN 03 2002

TECH CENTER 1600/2900

Applicant: Weiner et al.
Serial No: 09/809,745
Filed: March 15, 2001
For: SUPPRESSION OF VASCULAR DISORDERS BY MUCOSAL
ADMINISTRATION OF HEAT SHOCK PROTEIN PEPTIDES
Examiner: Unknown
Art Unit: 1646

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on November 30, 2001.

Yvonne M. Lingo
Yvonne M. Lingo

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. § 1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application but before the mailing date of the first Office Action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

No fee is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

PART III: Remarks

Documents cited on the attached form PTO-1449 (modified) are enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.


An early and favorable action is hereby requested.

Respectfully submitted,
Weiner et al., Applicant(s)

By: 
Alan W. Steele, Reg. No. 45, 128
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. B0801/7202
Dated: November 30, 2001
xNDD

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 09/809,745		ATTY. DOCKET NO.: B0801/7202	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: March 15, 2001			
				APPLICANT: Weiner et al.			
				GROUP ART UNIT: 1646		EXAMINER: Unknown	
Sheet	1	of	1				



RECEIVED
 JAN 03 2002
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C37	BERBERIAN PA et al., Immunohistochemical localization of heat shock protein-70 in normal-appearing and atherosclerotic specimens of human arteries. <i>Am J Pathol.</i> 1990 Jan; 136(1):71-80.	
	C38	JOHNSON AD et al., Atherosclerosis alters the localization of HSP70 in human and macaque aortas. <i>Exp Mol Pathol.</i> 1993 Jun;58(3):155-68.	
	C39	JOHNSON AD et al., Differential distribution of 70-kD heat shock protein in atherosclerosis. Its potential role in arterial SMC survival. <i>Arterioscler Thromb Vasc Biol.</i> 1995 Jan; 15(1):27-36.	
	C40	JOHNSON AD et al., Effect of heat shock proteins on survival of isolated aortic cells from normal and atherosclerotic cynomolgus macaques. <i>Atherosclerosis.</i> 1990 Oct; 84(2-3): 111-9.	

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. § 120, and the copy was provided in the earlier application.]